Posted by Michael Wonder on 01 Aug 2025
BeOne Medicines receives PRIME designation from the EMA for BGB-16673 in Waldenström’s macroglobulinaemia
31 July 2025 - Decision highlights the promise of BGB-16673, an investigational and potentially first in class BTK degrader designed to overcome resistance and deepen responses in B-cell malignancies
BeOne Medicines today announced that the EMA has granted PRIority MEdicines (PRIME) designation to the Company’s investigational Bruton’s tyrosine kinase degrader, BGB-16673, for the treatment of patients with Waldenström’s macroglobulinaemia previously treated with a BTK inhibitor.
